晟斯（上海）生物制药有限公司

Chinese biopharmaceutical company established on 24 February 2021 at Liangyao Road in Xinchang town, Pudong New Area, Shanghai with one hundred million yuan of registered capital, part of the Gensciences group whose Jiangsu company was founded in April 2020. The group develops innovative medicines for unmet clinical needs in haemophilia, metabolic disease and oncology and combines innovative drug research, clinical development, manufacturing and commercialisation with research and production bases in Beijing, Zhengzhou and Shanghai. Its long acting recombinant coagulation factor VIII has reached phase three clinical study and an ultra long acting recombinant factor VIII has been filed for clinical trials.